<SEC-DOCUMENT>0001104659-21-100768.txt : 20210805
<SEC-HEADER>0001104659-21-100768.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805161625
ACCESSION NUMBER:		0001104659-21-100768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		211148416

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2118570d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):&nbsp;August 5, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-12584</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3808303</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite 270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(301) 417-4364</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02. &ndash; Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 5, 2021, Synthetic
Biologics, Inc., a Nevada corporation (the &ldquo;Registrant&rdquo;) issued a press release that included financial information for its
quarter ended June 30, 2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information
contained in the press release is being furnished to the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) and shall not
be deemed incorporated by reference into any of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. &ndash; Financial Statements and Exhibits.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>(d)</B></TD><TD STYLE="text-align: justify"><B>Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 89%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top; padding-right: 0.8pt"><A HREF="tm2118570d2_ex99-1.htm" STYLE="-sec-extract: exhibit">

    99.1</A></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><A HREF="tm2118570d2_ex99-1.htm" STYLE="-sec-extract: exhibit">

    Press Release issued by Synthetic Biologics, Inc., dated August 5, 2021
    </A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Dated: August 5, 2021</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 3%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 5%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">and Chief Financial Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2118570d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2118570d2_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports Second Quarter 2021
Operational Highlights and Financial Results; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Conference Call to be Held Today at 4:30 PM
ET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Phase 1 Single-Ascending Dose Clinical Trial
of SYN-020 Demonstrated Favorable Safety Profile </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>and was Well Tolerated at All Dose Levels; A
Second Phase 1 Multiple-Ascending Dose Clinical Trial Expected to Commence in Q3 2021</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Enrollment in Phase 1b/2a Clinical Trial of
SYN-004 in Allogeneic HCT Recipients Proceeding as Planned</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Reports $74.3 Million of Cash on Hand to Fund
Clinical Programs Through Key Milestones Beyond 2022 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, August 5, 2021 &ndash;</B></FONT> <U>Synthetic Biologics, Inc</U>. <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a
diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (&ldquo;GI&rdquo;)
diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today provided a clinical programs update and reported financial
results for the second quarter ended June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recent Developments</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Announced completion of patient dosing and observation in the Phase 1, open label, single-ascending dose
(&ldquo;SAD&rdquo;) clinical trial of SYN-020 intestinal alkaline phosphatase (&ldquo;IAP&rdquo;)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Continuing enrollment in the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic
cell transplant (&ldquo;HCT&rdquo;) recipients</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Current cash position of approximately $74.3 million</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Current cash runway expected to provide funding to complete Phase 1b/2a
clinical trial of SYN-004, clinical trials of SYN-020 </FONT>through proof-of-concept, and other key milestones into 2023</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Anticipated Milestones:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>&nbsp;</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Expect to commence second Phase 1 multiple-ascending dose (&ldquo;MAD&rdquo;) clinical trial of SYN-020
during Q3 2021; topline data anticipated during Q2 2022</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Topline data readout from the first antibiotic cohort of the SYN-004 Phase 1b/2a clinical trial is expected
during Q4 2021</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;During the second quarter, we remained
focused on the advancement of our portfolio of gastrointestinal and microbiome-focused clinical programs,&rdquo; said Steven A. Shallcross,
Chief Executive Officer of Synthetic Biologics. &ldquo;We were pleased to complete patient dosing and observation in the Phase 1 SAD clinical
trial of SYN-020 intestinal alkaline phosphatase with preliminary results demonstrating that SYN-020 maintained a favorable safety profile,
was well tolerated at all dose levels, and no adverse events were attributed to SYN-020. Looking ahead, we intend to commence a second
Phase 1 MAD clinical trial of SYN-020 in healthy adult volunteers during the third quarter of 2021 with topline results expected during
the second quarter of 2022. Both the Phase 1 SAD and MAD studies are designed to support the advancement of SYN-020 in multiple potential
therapeutic indications, including celiac disease, nonalcoholic fatty liver disease (&ldquo;NAFLD&rdquo;), radiation enteritis, and age-related
metabolic and inflammatory diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Shallcross continued, &ldquo;Patient screening
and enrollment in the SYN-004 Phase 1b/2a clinical trial in allogeneic HCT recipients remains ongoing at the Washington University School
of Medicine in St. Louis (&ldquo;Washington University&rdquo;). At this time, enrollment is proceeding as expected and we anticipate announcing
topline results from this first of three antibiotic cohorts during the fourth quarter of 2021. We believe SYN-004 has the potential to
significantly improve outcomes for allogeneic HCT recipients by preventing downstream complications often caused by disruption of the
gut microbiome by intravenous (&ldquo;IV&rdquo;) beta-lactam antibiotics following conditioning therapy. We are very excited about the
potential for our portfolio of clinical development programs to be long-term value drivers for our Company and look forward to sharing
important updates as they become available.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Development and Operational Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Announced completion of patient dosing and observation in the Phase 1, open label, single-ascending dose
clinical trial of SYN-020</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 1 SAD study enrolled 24 healthy adult volunteers into four cohorts with SYN-020 given orally
as single doses ranging from 5 mg to 150 mg.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile, was well
tolerated at all dose levels, and no adverse events were attributed to the study drug. No serious adverse events were reported.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A second Phase 1 clinical trial evaluating multiple-ascending doses of SYN-020 in healthy volunteers is
expected to commence during the third quarter of 2021. Topline data are anticipated during the second quarter of 2022, pandemic conditions
permitting.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Both studies are intended to support the development of SYN-020 in multiple potential clinical indications
including celiac disease, NAFLD, radiation enteritis, as well as indications supported by the Company&rsquo;s collaboration with Massachusetts
General Hospital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Enrollment in the Company&rsquo;s Phase 1b/2a clinical trial of SYN-004 in allogeneic HCT recipients for
the prevention of acute graft-versus-host-disease (&ldquo;aGVHD&rdquo;) remains ongoing</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 1b/2a clinical trial comprises a single center, randomized, double-blind, placebo-controlled
clinical trial of oral SYN-004 in up to 36 evaluable adult allogeneic HCT recipients.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The goal of this clinical trial is to evaluate the safety, tolerability, and potential absorption into
the systemic circulation (if any) of oral SYN-004 administered to allogeneic HCT recipients who receive an IV beta-lactam antibiotic to
treat fever.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Study participants will be enrolled into three sequential cohorts and administered a different study-assigned
IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 and four will receive placebo.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety Monitoring
Committee (&ldquo;DSMC&rdquo;), which will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A topline data readout for the first antibiotic cohort is anticipated during the fourth quarter of 2021,
pandemic conditions permitting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Received notification from the NYSE American that the Company had regained compliance with all of the
continued listing standards set forth in Part 10, Section 1003 of the NYSE American Company Guide (the &ldquo;Company Guide&rdquo;) relating
to the Exchange&rsquo;s continued listing requirements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Quarter Ended June 30, 2021 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses decreased
by 2% to approximately $1.26 million for the three months ended June 30, 2021, from approximately $1.29 million for the three months ended
June 30, 2020. This decrease is primarily due to lower legal costs and vacation expense offset by higher insurance costs, audit fees and
registration fees. The charge related to stock-based compensation expense was $83,000 for the three months ended June 30, 2021, compared
to $67,000 for the three months ended June 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
by 21% to approximately $1.9 million for the three months ended June 30, 2021, from approximately $1.6 million for the three months
ended June 30, 2020. This increase is primarily the result of increased clinical trial expenses as we began dosing patients in the
Phase 1b/2a clinical trial of SYN-004 and Phase 1 SAD clinical trial of SYN-020 during the three months ended June 30, 2021, offset
by lower indirect program costs for the three months ended June 30, 2021, including salary and related expense reductions, a
decrease in manufacturing costs for SYN-020 and market research. In addition, as a result of the global COVID-19 pandemic, our
clinical development partner (Washington University) reduced their operating capacity during 2020 to include only essential
activities as part of their pandemic response, which delayed the start of our clinical trial until 2021. We anticipate research and
development expense to increase as our ongoing clinical trials continue to enroll patients. The charge related to stock-based
compensation expense was $19,000 for the three months ended June 30, 2021, compared to $19,000 related to stock-based compensation
expense for the three months ended June 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $2,000 for the three months ended
June 30, 2021, compared to other income of $6,000 for the three months ended June 30, 2020. Other income for the three months ended June
30, 2021 and 2020 is primarily comprised of interest income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents as of June 30, 2021
totaled $74.3 million, an increase of $68.1 million from December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Synthetic Biologics will hold a conference call
today, Thursday, August 5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">, 2021, at 4:30
p.m. (EST).</FONT> The dial-in information for the call is as follows, U.S. toll free: 1-888-347-5280 or International: +1 412-902-4280.
Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet
at <U>https://www.webcaster4.com/Webcast/Page/1096/41790</U>. An archive of the call will be available for replay at the same URL, <U>https://www.webcaster4.com/Webcast/Page/1096/41790
</U>, for 90 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American: SYN)
is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade
certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage,
(b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance
(AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020,
a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat
both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><BR>
</I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions, and include statements regarding
the current cash runway providing funding to complete the Phase 1b/2a clinical trial of SYN-004, clinical trials of SYN-020 through proof-of-concept,
and other key milestones into 2023, the Phase 1 clinical trials of SYN-020 supporting development of SYN-020 in multiple potential clinical
indications, commencing a second Phase 1 multiple ascending-dose (&ldquo;MAD&rdquo;) study of SYN-020 during Q3 2021 and topline data
anticipated during Q2 2022, a topline data readout from the first of three antibiotic cohorts of the SYN-004 Phase 1b/2a clinical trial
during Q4 2021, SYN-004 having the potential to significantly improve outcomes for allogeneic HCT recipients by preventing downstream
complications often associated with disruption of the gut microbiome by intravenous (&ldquo;IV&rdquo;) beta-lactam antibiotics following
conditioning therapy. These forward-looking statements are based on management&rsquo;s expectations and assumptions as of the date of
this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual
results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ materially from current expectations include, among others, a failure to receive
the necessary regulatory approvals for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo;
clinical trials for SYN-004 and SYN-020 to be completed on time, to provide topline data when anticipated or to achieve desired results
and benefits, especially in light of COVID-19, a failure of Synthetic Biologics&rsquo; clinical trials to continue enrollment as expected
or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics&rsquo;
inability to maintain its material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully
commercialize products and other factors described in Synthetic Biologics&rsquo; Annual Report on Form 10-K for the year ended December
31, 2020 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release
is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240) 660-2000,
<U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Synthetic Biologics,
Inc. and Subsidiaries</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>(in thousands, except
share and per share amounts)</I></B></P>



<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the three months ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 30, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2021</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">74,291</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,227</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,341</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,707</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">132</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Right of Use Asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,468</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">279</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">77,255</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,410</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholder&rsquo;s Deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,524</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,152</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Series A Convertible Preferred Stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,798</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.1in">Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">76,505</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,767</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.1in">Non-controlling interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,774</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,773</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">77,255</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,410</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><BR STYLE="clear: both">
</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Condensed Consolidated Statements of Operations</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(In thousands except share and per share amounts)</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended<BR> June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the six months ended<BR> June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,265</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,286</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,685</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,679</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,932</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,603</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,049</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,238</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,197</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,889</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,734</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,917</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,197</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,889</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,734</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,917</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><B>Net Loss </B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,195</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,883</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,732</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,873</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(42</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,195</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,867</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,731</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,831</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;Series A Preferred Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(125</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;Effect of Series A Preferred Stock price adjustment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,402</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&nbsp;&nbsp;Series B Preferred Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(392</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,497</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(796</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,195</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,322</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,654</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,752</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share &ndash; Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.38</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Weighted average number of common shares outstanding - Basic and Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">132,042,538</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,405,884</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,539,024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,748,688</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2118570d2_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2118570d2_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- /8# 2(  A$! Q$!_\0
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M\(:?JWBK69KD3"WT/P=INMZW?8AFM$6W9&DR/@#_ ,%L?^">'[1_Q2TWX.^
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MM4"F[T/46M]+\3:< 1YVC3R+NO0?[VANSZE@$;HS(A.TD5S7QZ^ ?C/]G[Q
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M91%$M]X?C/<;(3K@QP/FX QFO[*\5,+'Q]^C[PSXO8W#Y=3\1^!,93RKB_\
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M)R>'O"7"7%F*EC,3B,?0QM)9CA^*Z6!P#P6%K0^L8)R3KNNZ-#ZZ\2?LP?\
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MMUK?CG6;:: 36FN^)IFM[/PII10AA-:V$:^(-4UJ(H01_9&G2+)#K,H3^@_
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MP%\2-(@USP_J2P31H["/4-*O8]Z6VK:/>K^^TG4;23=+!J4#)+$4;:V-P/\
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J29)YSF1R/TQCVHJ:BO6=KNR271)62\DNB..3YFY.R;;=EHM>RZ+L?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
